GLYCO-IMMUNE CHECKPOINT INHIBITORS
Targeting Glycan-Sensing Checkpoints to Unleash Both the Innate and Adaptive Immune Responses to Cancer
GLYCO-IMMUNE CHECKPOINT INHIBITORS
The Need
Despite the early success of first-generation immuno-oncology drugs, most cancer patients still do not achieve clinical responses.
The Scientific Opportunity
Cell surface glycosylation is now known to play a central role in immuno-oncology: Tumor cells evolve over time, cloaking themselves in certain glycan patterns that down-regulate a wide spectrum of innate and adaptive immune cell types which are critical to fighting cancer.
The Approach
Palleon Pharmaceuticals has integrated technologies and insights from world-renowned scientific leaders in glycoscience and human immunology to create the first Glyco-Immune Checkpoint Inhibitors to treat cancer patients.
News
Palleon Pharmaceuticals Announces Preclinical Data from EAGLE Platform to be Presented at the Society for Immunotherapy of Cancer Annual Meeting
June 21, 2018Palleon Pharmaceuticals Appoints Lori Hu of Vertex Ventures HC to Board of Directors
Twitter
@Palleon_Pharma
We're pleased to see research that focuses on #glycans as a new therapeutic opportunity. Check out this article fro… http://rKDLoVw2vA
@Palleon_Pharma
We’re excited to have our team's work included in #SITC2018’s Scientific Highlights, #ICYMI read more about our VP… http://qt20rpg3Ar